<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942005</url>
  </required_header>
  <id_info>
    <org_study_id>11/10</org_study_id>
    <nct_id>NCT01942005</nct_id>
  </id_info>
  <brief_title>EVER(Epidermodysplasia Verruciformis Levandowsky-Lutz)/TMC(TransMembral Channel Like Protein) Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients</brief_title>
  <official_title>EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andreas Arnold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Detection of mutation  / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

      correlation between possibly detected mutation/specific polymorphism and kind and number of
      neoplasm, age of patients, UV burden, duration and kind of immunosuppression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">377</enrollment>
  <condition>Immunosuppression</condition>
  <condition>Neoplasm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients who underwent organ transplatation or patients who have a HIV infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients in an immunosuppressive condition either by immunosuppressants or by HIV
             infection

        Exclusion Criteria:

          -  written informed consent not given
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Dermatology, CH-4031 Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Arnold, MD</last_name>
    <phone>+41 61 328 67 69</phone>
    <email>andreas.arnold@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel, Dermatology</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Arnold, MD</last_name>
      <phone>+41 61 328 67 69</phone>
      <email>andreas.arnold@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Andreas Arnold</investigator_full_name>
    <investigator_title>Dr. med. Andreas Arnold, senior physician</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Epidermodysplasia Verruciformis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
